Q&A With Vincenzo La Mura From University of Milan: Cirrhosis and its Benefit-Risk Ratios


Anticoagulants may not be the ideal treatment for all patients with cirrhosis and portal hypertension but research is being done to find the best possible treatments for these patients.

Vincenzo La Mura, University of Milan focused his latest research on the clinical and pathophysiological aspects associated with cirrhosis and portal hypertension to better understand which subset of patients truly benefit from anticoagulation treatment.

La Mura presented the results of his research When the European Association for the Study of Liver held its 50th Annual Liver Congress in Vienna.

Related Videos
Gestational Low-Dose Aspirin Does Not Increase Risk of IBD Flares in Women
Riha Bhatt, MD: Mimickers and Concurrent Diseases in Pediatric IBD
Elizabeth Spencer, MD: Precision Medicine in Pediatric IBD
Anita Clayton, MD: Zuranolone for Postpartum Depression
Mikkael Sekeres, MD:
© 2023 MJH Life Sciences

All rights reserved.